StockData
OPKO Health, Inc. logo

OPKO Health, Inc. (OPK) stock

OPKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/305% above fair value
$1.62+0.00 (0.00%)

Close on Nov 17, 2026Market cap $1.21BP/E –Yield –

Earnings

OPKO Health's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 25, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$65.40M
-56.9% on a year earlier
EPS, Q3 FY2026
-$0.05
$0.03 a year earlier
Latest guidance
Raised
Nov 4, 2026 · 16 items

Quarterly results

Revenue and earnings per share from each of OPKO Health's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 25, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 4, 2026after the close$65.40M-56.9%-$0.05Release
Q2 FY2026ended Jun 30, 2026Jul 27, 2026after the close$163.50M+4.3%-$0.01Release
Q1 FY2026ended Mar 31, 2026Apr 28, 2026after the close$124.20M-17.1%-$0.07Release
Q4 FY2025ended Dec 31, 2025Feb 26, 2026after the close$148.50M-19.1%-$0.04Release
Q3 FY2025ended Sep 30, 2025Oct 29, 2025after the close$151.70M-12.6%$0.03Release
Q2 FY2025ended Jun 30, 2025Jul 31, 2025after the close$156.80M-13.9%-$0.19Release
Q1 FY2025ended Mar 31, 2025Apr 30, 2025after the close$149.90M-13.7%-$0.10Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025after the close$183.60M+0.9%$0.01Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024after the close$173.60M-2.8%$0.03Release
Q2 FY2024ended Jun 30, 2024Aug 7, 2024after the close$182.20M-31.3%-$0.01Release
Q1 FY2024ended Mar 31, 2024May 7, 2024after the close$173.70M-26.9%-$0.12Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

OPKO Health's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Total revenueQ4 FY2026$62.00M – $72.00M–NewNov 4, 2026
BARDAQ4 FY2026$3.00M – $5.00M–LoweredNov 4, 2026
Income/(loss) from discontinued operationsQ4 FY2026-$45.00M – -$35.00M–LoweredNov 4, 2026
IP and other revenueQ4 FY2026$21.00M – $27.00M–LoweredNov 4, 2026
Pfizer gross profit shareQ4 FY2026$12.50M – $15.00M–LoweredNov 4, 2026
Product revenueQ4 FY2026$41.00M – $46.00M–NewNov 4, 2026
R&D included in costs and expensesQ4 FY2026$32.00M – $35.00M–LoweredNov 4, 2026
Total costs and expenses [from continuing operations]Q4 FY2026$100.00M – $105.00M–RaisedNov 4, 2026
Services revenueFY2026$296.00M – $306.00M$300.00M – $312.00MRaisedJul 27, 2026
Total revenueFY2026$268.00M – $278.00M–NewNov 4, 2026
BARDAFY2026$20.00M – $22.00M–LoweredNov 4, 2026
Income/(loss) from discontinued operationsFY2026-$70.00M – -$60.00M–LoweredNov 4, 2026
IP and other revenueFY2026$105.00M – $110.00M–LoweredNov 4, 2026
Pfizer gross profit shareFY2026$34.00M – $37.00M–LoweredNov 4, 2026
Product revenueFY2026$164.00M – $169.00M–NewNov 4, 2026
R&D included in costs and expensesFY2026$125.00M – $130.00M–LoweredNov 4, 2026
R&D included in costs and expensesFY2026$125.00M – $135.00M$125.00M – $135.00MLoweredJul 27, 2026
Total costs and expensesFY2026$710.00M – $740.00M$725.00M – $750.00MRaisedJul 27, 2026
Total costs and expenses [from continuing operations]FY2026$390.00M – $395.00M–RaisedNov 4, 2026

Guidance vs results

The last range OPKO Health gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
Q3 FY2026Revenue$73.00M – $78.00M$65.40MBelow range
Q2 FY2026Revenue$72.00M – $76.00M$163.50MAbove range
Q1 FY2026Revenue$15.00M – $20.00M$124.20MAbove range

Guidance history

Every forecast OPKO Health put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 4, 2026Product revenueQ4 FY2026$41.00M – $46.00MNew
Nov 4, 2026IP and other revenueQ4 FY2026$21.00M – $27.00MLowered
Nov 4, 2026Pfizer gross profit shareQ4 FY2026$12.50M – $15.00MLowered
Nov 4, 2026BARDAQ4 FY2026$3.00M – $5.00MLowered
Nov 4, 2026Total costs and expenses [from continuing operations]Q4 FY2026$100.00M – $105.00MRaised
Nov 4, 2026R&D included in costs and expensesQ4 FY2026$32.00M – $35.00MLowered
Nov 4, 2026Income/(loss) from discontinued operationsQ4 FY2026-$45.00M – -$35.00MLowered
Nov 4, 2026Product revenueFY2026$164.00M – $169.00MNew
Nov 4, 2026IP and other revenueFY2026$105.00M – $110.00MLowered
Nov 4, 2026Pfizer gross profit shareFY2026$34.00M – $37.00MLowered
Nov 4, 2026BARDAFY2026$20.00M – $22.00MLowered
Nov 4, 2026Total costs and expenses [from continuing operations]FY2026$390.00M – $395.00MRaised
Nov 4, 2026R&D included in costs and expensesFY2026$125.00M – $130.00MLowered
Nov 4, 2026Income/(loss) from discontinued operationsFY2026-$70.00M – -$60.00MLowered
Nov 4, 2026Total revenueQ4 FY2026$62.00M – $72.00MNew
Nov 4, 2026Total revenueFY2026$268.00M – $278.00MNew
Jul 27, 2026Total costs and expensesFY2026$710.00M – $740.00MRaised
Jul 27, 2026R&D included in costs and expensesFY2026$125.00M – $135.00MLowered
Jul 27, 2026Total costs and expensesQ3 FY2026$180.00M – $190.00MNew
Jul 27, 2026R&D included in costs and expensesQ3 FY2026$34.00M – $38.00MLowered

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases OPKO Health filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. Results
  6. Update
  7. Results
  8. Results
  9. Update
  10. Results
  11. Update
  12. Results
  13. Update
  14. Update
  15. Results

See a number that looks wrong?